Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Praxis Precision Medicines (PRAX) Equity Average (2022 - 2025)

Praxis Precision Medicines has reported Equity Average over the past 4 years, most recently at $610.8 million for Q4 2025.

  • Quarterly results put Equity Average at $610.8 million for Q4 2025, up 47.52% from a year ago — trailing twelve months through Dec 2025 was $610.8 million (up 47.52% YoY), and the annual figure for FY2025 was $661.8 million, up 156.95%.
  • Equity Average for Q4 2025 was $610.8 million at Praxis Precision Medicines, up from $373.9 million in the prior quarter.
  • Over the last five years, Equity Average for PRAX hit a ceiling of $610.8 million in Q4 2025 and a floor of $70.3 million in Q1 2023.
  • Median Equity Average over the past 4 years was $164.9 million (2022), compared with a mean of $256.3 million.
  • Biggest five-year swings in Equity Average: plummeted 48.44% in 2023 and later skyrocketed 429.4% in 2024.
  • Praxis Precision Medicines' Equity Average stood at $90.6 million in 2022, then dropped by 13.71% to $78.2 million in 2023, then skyrocketed by 429.4% to $414.1 million in 2024, then soared by 47.52% to $610.8 million in 2025.
  • The last three reported values for Equity Average were $610.8 million (Q4 2025), $373.9 million (Q3 2025), and $421.7 million (Q2 2025) per Business Quant data.